Report of the International Stem Cell Banking Initiative Workshop Activity: Current Hurdles and Progress in Seed-Stock Banking of Human Pluripotent Stem Cells

Jung-Hyun Kim; Andreas Kurtz; Bao-Zhu Yuan; Fanyi Zeng; Geoff Lomax; Jeanne F Loring; Jeremy Crook; Ji Hyeon Ju; Laura Clarke; Maneesha S Inamdar; Martin Pera; Meri T Firpo; Michael Sheldon; Nafees Rahman; Orla O'Shea; Patricia Pranke; Qi Zhou; Rosario Isasi; Ruttachuk Rungsiwiwut; Shin Kawamata; Steve Oh; Tenneille Ludwig; Tohru Masui; Thomas J Novak; Tsuneo Takahashi; Wataru Fujibuchi; Soo Kyung Koo; Glyn N Stacey

doi:10.1002/sctm.17-0144

Report of the International Stem Cell Banking Initiative Workshop Activity: Current Hurdles and Progress in Seed-Stock Banking of Human Pluripotent Stem Cells

Stem Cells Transl Med. 2017 Nov;6(11):1956-1962. doi: 10.1002/sctm.17-0144. Epub 2017 Oct 24.

Authors

Jung-Hyun Kim¹, Andreas Kurtz², Bao-Zhu Yuan³, Fanyi Zeng⁴, Geoff Lomax⁵, Jeanne F Loring⁶, Jeremy Crook^{7

8

9}, Ji Hyeon Ju¹⁰, Laura Clarke¹¹, Maneesha S Inamdar¹², Martin Pera¹³, Meri T Firpo¹⁴, Michael Sheldon¹⁵, Nafees Rahman¹⁶, Orla O'Shea¹⁷, Patricia Pranke¹⁸, Qi Zhou¹⁹, Rosario Isasi²⁰, Ruttachuk Rungsiwiwut²¹, Shin Kawamata²², Steve Oh²³, Tenneille Ludwig²⁴, Tohru Masui²⁵, Thomas J Novak²⁶, Tsuneo Takahashi²⁷, Wataru Fujibuchi²⁸, Soo Kyung Koo¹, Glyn N Stacey¹⁷

Affiliations

¹ Korea Stem Cell Bank, Center for Biomedical Sciences, Korea National Institute of Health (KNIH), Osong, South Korea.
² Charité Universitätsmedizin Berlin, Berlin, Germany.
³ Cell Collection and Research Center, National Institutes for Food and Drug Control, Beijing, China.
⁴ Shanghai Institute of Medical Genetics, Shanghai Jiao Tong University, Shanghai, China.
⁵ California Institute for Regenerative Medicine, Oakland, CA, USA.
⁶ Department of Molecular Medicine Center for Regenerative Medicine The Scripps Research Institute, San Diego, CA, USA.
⁷ ARC Centre of Excellence for Electromaterials Science, Intelligent Polymer Research Institute, AIIM Facility, University of Wollongong, Fairy Meadow, New South Wales, Australia.
⁸ Illawarra Health and Medical Research Institute, University of Wollongong, Wollongong, New South Wales, Australia.
⁹ Department of Surgery, St. Vincent's Hospital, The University of Melbourne, Fitzroy, Victoria, Australia.
¹⁰ Catholic University, Seoul, Korea.
¹¹ European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, Cambridge, UK.
¹² Molecular Biology and Genetics Unit, Jawaharlal Nehru Centre for Advanced Scientific Research, Bangalore, India.
¹³ Jackson Laboratories, Bar Harbor, ME, USA.
¹⁴ Stem Cell Institute and Department of Medicine, University of Minnesota, Minneapolis, MN, USA.
¹⁵ Department of Genetics, Rutgers, The State University of New Jersey, Piscataway, NJ.
¹⁶ University of Toronto, Toronto, Ontario, Canada.
¹⁷ UK Stem Cell Bank, Division of Advanced Therapies, NIBSC, South Mimms, UK.
¹⁸ Stem Cell Research Institute, Federal University of Rio Grande do Sul, Porto Alegre, Brazil.
¹⁹ Institute of Zoology, Chinese Academy of Sciences, Beijing, China.
²⁰ Department of Human Genetics, University of Miami Miller School of Medicine, Miami, FL, USA.
²¹ Department of Obstetrics and Gynecology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
²² Foundation for Biomedical Research and Innovation, Kobe, Japan.
²³ Stem Cell Group, Bioprocessing Technology Institute, A*STAR, Singapore.
²⁴ WiCell Research Institute, Madison, WI, USA.
²⁵ Keio University/SKIP, Yokahama, Japan.
²⁶ Cellular Dynamics International, Madison, WI, USA.
²⁷ University of Kyoto, Kyoto, Japan.
²⁸ Department of Cell Growth and Differentiation, Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan.

Abstract

This article summarizes the recent activity of the International Stem Cell Banking Initiative (ISCBI) held at the California Institute for Regenerative Medicine (CIRM) in California (June 26, 2016) and the Korean National Institutes for Health in Korea (October 19-20, 2016). Through the workshops, ISCBI is endeavoring to support a new paradigm for human medicine using pluripotent stem cells (hPSC) for cell therapies. Priority considerations for ISCBI include ensuring the safety and efficacy of a final cell therapy product and quality assured source materials, such as stem cells and primary donor cells. To these ends, ISCBI aims to promote global harmonization on quality and safety control of stem cells for research and the development of starting materials for cell therapies, with regular workshops involving hPSC banking centers, biologists, and regulatory bodies. Here, we provide a brief overview of two such recent activities, with summaries of key issues raised. Stem Cells Translational Medicine 2017;6:1956-1962.

Keywords: Data standardization; Human embryonic stem cell (hESC); Human pluripotent stem cells; Induced pluripotent stem cell (iPSC); Informed consents; Quality assurance; Quality control; Stem cell banking.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Biological Specimen Banks / organization & administration
Biological Specimen Banks / standards*
Congresses as Topic
Human Embryonic Stem Cells / cytology*
Humans
International Cooperation
Stem Cell Research*